Phenytoin in the treatment of cocaine abuse: A double-blind study

Clinical Pharmacology and Therapeutics

Volumn 59, Issue 4, 1996, Pages 458-468

  Crosby, Ross D ^a   Pearson, Victoria L ^b   Eller, Carl ^b   Winegarden, Thomas ^b   Graves, Nina L ^b  

^a NCS Assessments   (United States)

^b NCS Assessment ^*

Author keywords

[No Author keywords available]

Indexed keywords

COCAINE; PHENYTOIN; PLACEBO;

ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG ABUSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG THERAPY; FEMALE; HUMAN; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; ANTICONVULSANTS; COCAINE; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; PATIENT COMPLIANCE; PHENYTOIN; SUBSTANCE-RELATED DISORDERS;

EID: 0029880735     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(96)90116-2     Document Type: Article

References (55)

1. Rouse BA. Trends in cocaine use in the general population. National Institute on Drug Abuse Research Monograph Series. Washington: US Government Printing Office; 1991;110:5-18.
2. Voss HL. Patterns of drug use: data from the 1985 National Household Survey. National Institute on Drug Abuse Research Monograph Series. Washington: US Government Printing Office; 1989;91:33-46.
3. Abelson HI, Miller JD. A decade of trends in cocaine use in the household population. National Institute on Drug Abuse Research Monograph Series. Washington: US Government Printing Office; 1985;61:35-49.
4. Substance Abuse and Mental Health Services Administration. Preliminary estimates from the 1992 National Household survey on Drug Abuse. Washington: US Government Printing Office, 1993.
5. Epidemiologic trends in drug abuse. Community epidemiology work group. Rockville, Maryland: National Institute on Drug Abuse; 1993; publication no 94-3739.
6. Gold MS. Cocaine (and crack): clinical aspects. In: Lowinson JH, Ruiz P, Millman RB, Langrod JG, eds. Substance abuse: a comprehensive textbook. 2nd ed. Baltimore: Williams & Wilkins, 1992.
7. Smart RG. Crack cocaine use: a review of prevalence and adverse effects. Am J Drug Alcohol Abuse 1991; 17:13-26.
8. Gorelick DA. Pathophysiological effects of cocaine in humans: review of scientific issues. J Addict Dis 1992; 11:97-110.
9. Goldfrank LR, Hoffman RS. The cardiovascular effects of cocaine - update 1992. National Institute on Drug Abuse Research Monograph Series. Washington: US Government Printing Office; 1992;123:70-109.
10. Miller BL, Chiang F, McGill L, Sadow T, Goldberg MA, Mena I. Cerebrovascular complications from cocaine: possible long-term sequelae. National Institute on Drug Abuse Research Monograph Series 1992; 123:129-46.
11. Johnson BD, Muffler J. Sociocultural aspects of drug use and abuse in the 1990s. In: Lowinson JH, Ruiz P, Millman RB, Langrod JG, eds. Substance abuse: a comprehensive textbook. 2nd ed. Baltimore: Williams & Wilkins, 1992.
12. Rice DP, Kelman S, Miller LS. Economic costs of drug abuse. National Institute on Drug Abuse Research Monograph Series. Washington: US Government Printing Office; 1991;113:10-32.
13. Tims FM, Fletcher BW, Hubbard RL. Treatment outcomes for drug abuse clients. National Institute on Drug Abuse Research Monograph Series. Washington: US Government Printing Office; 1991;106:93-113.
14. Hubbard RL. Evaluation and treatment outcome. In: Lowinson JH, Ruiz P, Millman RB, Langrod JG, eds. Substance abuse: a comprehensive textbook. 2nd ed. Baltimore: Williams & Wilkins, 1992.
15. Alterman AI, McLellan AT. Inpatient and day hospital treatment services for cocaine and alcohol dependence. J Subst Abuse Treat 1993;10:269-75.
16. Alterman AI, McLellan AT, O'Brien CP, et al. Effectiveness and costs of inpatient versus day hospital cocaine rehabilitation. J Nerv Ment Dis 1994;182:157-63.
17. Price RH, Burke AC, D'Aunno TA, et al. Outpatient drug abuse treatment services, 1988: results of a national survey. National Institute on Drug Abuse Research Monograph Series. Washington: US Government Printing Office; 1991;106:63-91.
18. Kleinman PH, Woody GE, Todd TC, et al. Crack and cocaine abusers in outpatient psychotherapy. National Institute on Drug Abuse Research Monograph Series. Washington: US Government Printing Office; 1990; 104:24-34.
19. Crosby RD, Halikas JA, Carlson GA. Pharmacotherapeutic interventions for cocaine abuse: present practices and future directions. J Addict Dis 1991;10:13-29.
20. Tutton CS, Crayton JW. Current pharmacotherapies for cocaine abuse: a review. J Addict Dis 1993;12:109-27.
21. Kosten TR. Clinical and research perspectives on cocaine abuse: the pharmacotherapy of cocaine abuse. National Institute on Drug Abuse Research Monograph Series. Washington: US Government Printing Office; 1993;135:48-56.
22. Meyer RE. New pharmacotherapies for cocaine dependence . . . revisited. Arch Gen Psychiatry 1992;49: 900-4.
23. Halikas JA, Kemp KD, Kuhn KL, Carlson GA, Crea FS. Carbamazepine for cocaine addiction? [Letter]. Lancet 1989;March 18:623-4.
24. Halikas JA, Kuhn KL. A possible neurophysiological basis of cocaine craving. Ann Clin Psychiatry 1990;2: 79-83.
25. Post RM. Time course of clinical effects of carbamazepine: implication for mechanism of action. J Clin Psychiatry 1988;49:35-46.
26. Halikas JA, Kuhn KL, Carlson GA, Crea F, Crosby RD. The effect of carbamazepine on cocaine use. Am J Addict 1992;1:30-9.
27. Halikas JA, Kuhn K, Crea FS, Carlson GA, Crosby RD. Treatment of crack cocaine use with carbamazepine. Am J Drug Alcohol Abuse 1992;18:45-56.
28. Halikas JA, Kemp KD, Kuhn KL, Maddux TL. Reduction of cocaine use among methadone maintenance patients using concurrent carbamazepine maintenance. Ann Clin Psychiatry 1990;2:3-6.
29. Halikas JA, Crosby RD, Carlson GA, Crea F, Graves NM, Bowers LD. Cocaine reduction in unmotivated crack users using carbamazepine versus placebo in a short-term, double-blind crossover design. CLIN PHARMACOL THER 1991;50:81-95.
30. Crosby RD, Halikas JA, Graves NM, Pearson VL, Carlson GA. Carbamazepine in the treatment of cocaine abuse. Presented at the 146th Annual Meeting of the American Psychiatric Association, San Francisco, California, May 22-27, 1993.
31. Campbell JL, Thomas HM, Gabrielli W, Liskow BI, Powell BJ. Impact of desipramine or carbamazepine on patient retention in outpatient cocaine treatment: preliminary findings. J Addict Dis 1994;13:191-9.
32. Kranzler HR, Bauer LO, Hersh D, Klinghoffer V. Carbamazepine treatment of cocaine dependence: a placebo controlled trial. Drug Alcohol Depend 1995; 38:203-11.
33. Montoya ID, Levin FR, Fudala PJ, Goreelick DA. Double-blind comparison of carbamazepine and placebo for treatment of cocaine dependence. Drug Alcohol Depend 1995;38:213-9.
34. Cornish JW, Maany I, Fudala PJ, et al. Carbamazepine treatment for cocaine dependence. Drug Alcohol Depend 1995;38:221-7.
35. Lorenzo RD. Phenytoin mechanisms of action. In: Levy R, Mattson R, Meldrum B, Penry J, Dreifuss F, eds. Antiepileptic drugs. 3rd ed. New York: Raven Press, 1989.
36. Lothman EW, Williamson JM, VanLandingham KE. Intraperitoneal phenytoin suppresses kindles responses: effects on motor and electrographic seizures. Epilepsy Res 1991;9:11-8.
37. Rundfeldt C, Honack D, Loscher W. Phenytoin potently increases the threshold for focal seizures in amygdala-kindled rats. Neuropharmacology 1990;9: 845-51.
38. Diagnostic and statistical manual of mental disorders, third edition - revised. Washington: American Psychiatric Association, 1987.
39. Crosby RD, Halikas JA, Bowers LD. Quantitative cocaine urine testing in clinical research settings. Ann Clin Psychiatry 1991;3:243-9.
40. Halikas JA, Crosby RD. Measuring outcome in the treatment of cocaine abuse: the Drug Impairment Rating Scale of Cocaine. J Addict Dis 1991;11:121-38.
41. Halikas JA, Kuhn KL, Crosby RD, Carlson GA, Crea F. The measurement of craving in cocaine patients using the Minnesota Craving Scale. Compr Psychiatry 1990;32:22-7.
42. Gibbons RD, Hedeker D, Elkin I, et al. Some conceptual and statistical issues in analysis of longitudinal psychiatric data. Arch Gen Psychiatry 1993;50:739-50.
43. Stiratelli R, Laird NM, Ware JH. Random-effects models for serial observations with binary response. Biometrics 1984;40:961-71.
44. Gibbons RD, Bock RD. Trend in correlated proportions. Psychometrika 1987;52:113-24.
45. Kalbfleisch JD, Prentice RL. The statistical analysis of failure. New York: John Wiley, 1980.
46. Tozer TN, Winter ME. Phenytoin. In: Evans WE, Schentag JJ, Jusko WJ, Relling MV, eds. Applied pharmacokinetics: principles of therapeutic drug monitoring. 3rd ed. Vancouver, Washington: Applied Therapeutics, 1992.
47. Faingold CL, Browning RA. Mechanism of anticonvulsant drug action; I: drugs primarily used for generalized tonic-clonic and partial epilepsies. Eur J Pediatr 1987;146:2-7.
48. Volpicelli JR, Alterman AI, Hayashida M, O'Brien CP. Naltrexone in the treatment of alcohol dependence. Arch Gen Psychiatry 1992;49:876-80.
49. Mendelson J. Role of serotonin for pharmacotherapy of alcohol abuse. Annual meeting of the American College of Neuropsychopharmacology, San Juan, Puerto Rico, December 11, 1991.
50. Gawin FH, Kleber HD. Evolving conceptualizations of cocaine dependence. Yale J Biol Med 1988;61:123-36.
51. Weddington WW, Haertzen CA, Hess JM, Brown BS. Psychological reactions and retention by cocaine addicts during treatment according to HIV serostatus: a matched-control study. Am J Drug Alcohol Abuse 1991;17:355-68.
52. Arndt IO, Dorozynsky L, Woody GE, McLellan AT, O'Brien CP. Desipramine treatment of cocaine dependence in methadone maintained patients. Arch Gen Psychiatry 1992;49:888-93.
53. Kosten TR, Morgan CM, Falcione J, Schottenfeld RS. Pharmacotherapy for cocaine-abusing methadone-maintained patients using amantadine or desipramine. Arch Gen Psychiatry 1992;49:894-8.
54. Schwartz RH. Urine testing in the detection of drugs of abuse. Arch Intern Med 1988;148:2407-12.
55. Finkle BS. Drug-analysis technology: overview and state of the art. Clin Chem 1987;33(suppl 11):13B-17B.